Does Accelerating Clinical Research Trials Introduce Risk?

Oct 31, 2018 | Clinical Research, Clinical Trials, Patient Safety

Joel Clark writing for Raconteur writes a provocative piece raising the question that despite the importance of getting life prolonging treatments to patients more quickly, the acceleration of drug trials offers may overlook critical risks according to some physicians. Does accelerating trials mean faster but less reliable outcomes? Mr. Clark includes a quote from a University of Edinburgh clinical lecturer that “the combination of patient demand for life-saving drugs and the explosion of new medical techniques and treatments has put pressure on regulators to facilitate early access, and made them more disposed to rely on early phase data and surrogate end points. This doesn’t always translate into helping patients live longer.”  Read Mr. Clark’s story for more details into this very important topic and potential debate.


Pin It on Pinterest